{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T08:56:25Z","timestamp":1794300985396,"version":"4.9.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Tech Coloproctol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Perianal Crohn\u2019s disease (pCD) is a complex manifestation of Crohn\u2019s disease. Classifying this patient cohort for both clinical purposes and for inclusion into research trials is challenging but crucial in order to improve outcomes. This review provides an overview of historical classifications of both fistulising and non-fistulising pCD, including the Park\u2019s, Cardiff\u2013Hughes and American Gastroenterological Association (AGA) classifications, as well as recent advances including the Treatment Optimisation and CLASSification of perianal Crohn\u2019s disease (TOpClass) classification of fistulising pCD. Secondly, this article provides a scoping review of recent trials in pCD and describes how the cohorts in these trials relate to the TOpClass classification. Of the 19 studies relating to pCD that were identified, four could be confidently classified as class 2a. Seven could be classified as class 2a or 2b, but it was not possible to subdivide further, and seven to class 2a, 2b or 2c, but it was not possible to subdivide further. One study population was classified as class 2a or 2c. In eight studies, it was not specified whether patients with a defunctioning stoma were included or excluded. This review demonstrates the heterogeneous nature of some patient cohorts in previous clinical trials, and how the TOpClass classification may be used to group patients more accurately for clinical use and inclusion in research trials.<\/jats:p>","DOI":"10.1007\/s10151-025-03161-z","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T14:09:09Z","timestamp":1748268549000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Time to classify: a narrative and scoping review of the old and the new classifications of perianal Crohn\u2019s disease"],"prefix":"10.1007","volume":"29","author":[{"given":"T.","family":"Pelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Shakweh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Lung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Tozer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"3161_CR1","doi-asserted-by":"publisher","DOI":"10.1017\/9781107705784","volume-title":"The Cambridge companion to Hippocrates","author":"PE Pormann","year":"2018","unstructured":"Pormann PE (2018) The Cambridge companion to Hippocrates, 1st edn. Cambridge University Press, Cambridge","edition":"1"},{"key":"3161_CR2","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1053\/gast.2002.32362","volume":"122","author":"DA Schwartz","year":"2002","unstructured":"Schwartz DA, Loftus EV, Tremaine WJ et al (2002) The natural history of fistulizing Crohn\u2019s disease in Olmsted County, Minnesota. Gastroenterology 122:875\u2013880. https:\/\/doi.org\/10.1053\/gast.2002.32362","journal-title":"Gastroenterology"},{"key":"3161_CR3","doi-asserted-by":"publisher","first-page":"6379","DOI":"10.3390\/jcm12196379","volume":"12","author":"S Anandabaskaran","year":"2023","unstructured":"Anandabaskaran S, Hanna L, Iqbal N et al (2023) Where Are we and where to next? The future of perianal Crohn\u2019s disease management. J Clin Med 12:6379. https:\/\/doi.org\/10.3390\/jcm12196379","journal-title":"J Clin Med"},{"key":"3161_CR4","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1097\/00000658-193811000-00007","volume":"108","author":"A Penner","year":"1938","unstructured":"Penner A, Crohn BB (1938) Perianal fistulae as a complication of regional ileitis. Ann Surg 108:867\u2013873","journal-title":"Ann Surg"},{"key":"3161_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/bjs.1800630102","volume":"63","author":"AG Parks","year":"2005","unstructured":"Parks AG, Gordon PH, Hardcastle JD (2005) A classification of fistula-in-ano. Br J Surg 63:1\u201312. https:\/\/doi.org\/10.1002\/bjs.1800630102","journal-title":"Br J Surg"},{"key":"3161_CR6","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.gastro.2003.08.025","volume":"125","author":"WJ Sandborn","year":"2003","unstructured":"Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB (2003) AGA technical review on perianal Crohn\u2019s disease. Gastroenterology 125:1508\u20131530. https:\/\/doi.org\/10.1016\/j.gastro.2003.08.025","journal-title":"Gastroenterology"},{"key":"3161_CR7","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1007\/BF02253493","volume":"35","author":"LE Hughes","year":"1992","unstructured":"Hughes LE (1992) Clinical classification of perianal Crohn\u2019s disease. Dis Colon Rectum 35:928\u2013932. https:\/\/doi.org\/10.1007\/BF02253493","journal-title":"Dis Colon Rectum"},{"key":"3161_CR8","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S2468-1253(22)00007-3","volume":"7","author":"J Geldof","year":"2022","unstructured":"Geldof J, Iqbal N, LeBlanc J-F et al (2022) Classifying perianal fistulising Crohn\u2019s disease: an expert consensus to guide decision-making in daily practice and clinical trials. Lancet Gastroenterol Hepatol 7:576\u2013584. https:\/\/doi.org\/10.1016\/S2468-1253(22)00007-3","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3161_CR9","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1136\/gutjnl-2013-306709","volume":"63","author":"KB Gecse","year":"2014","unstructured":"Gecse KB, Bemelman W, Kamm MA et al (2014) A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn\u2019s disease. Gut 63:1381\u20131392. https:\/\/doi.org\/10.1136\/gutjnl-2013-306709","journal-title":"Gut"},{"key":"3161_CR10","doi-asserted-by":"publisher","first-page":"906","DOI":"10.7326\/0003-4819-135-10-200111200-00011","volume":"135","author":"DA Schwartz","year":"2001","unstructured":"Schwartz DA, Pemberton JH, Sandborn WJ (2001) Diagnosis and treatment of perianal fistulas in Crohn disease. Ann Intern Med 135:906\u2013918. https:\/\/doi.org\/10.7326\/0003-4819-135-10-200111200-00011","journal-title":"Ann Intern Med"},{"key":"3161_CR11","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gut.2005.082909","volume":"55","author":"J Satsangi","year":"2006","unstructured":"Satsangi J, Silverberg MS, Vermeire S, Colombel J (2006) The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 55:749\u2013753. https:\/\/doi.org\/10.1136\/gut.2005.082909","journal-title":"Gut"},{"key":"3161_CR12","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","volume":"340","author":"D Present","year":"1999","unstructured":"Present D, Rutgeerts P, Targan S et al (1999) Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease. N Engl J Med 340:1398\u20131405. https:\/\/doi.org\/10.1056\/NEJM199905063401804","journal-title":"N Engl J Med"},{"key":"3161_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/00004836-199501000-00008","volume":"20","author":"EJ Irvine","year":"1995","unstructured":"Irvine EJ (1995) Usual therapy improves perianal Crohn\u2019s disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 20:27\u201332","journal-title":"J Clin Gastroenterol"},{"key":"3161_CR14","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1148\/radiographics.20.3.g00mc15623","volume":"20","author":"J Morris","year":"2000","unstructured":"Morris J, Spencer JA, Ambrose NS (2000) MR imaging classification of perianal fistulas and its implications for patient management. Radiographics 20:623\u2013635. https:\/\/doi.org\/10.1148\/radiographics.20.3.g00mc15623","journal-title":"Radiographics"},{"key":"3161_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.06.047","author":"LN Hanna","year":"2024","unstructured":"Hanna LN, Anandabaskaran S, Iqbal N et al (2024) Perianal fistulizing Crohn\u2019s disease: utilizing the TOpClass classification in clinical practice to provide targeted individualized care. Clin Gastroenterol Hepatol. https:\/\/doi.org\/10.1016\/j.cgh.2024.06.047","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3161_CR16","doi-asserted-by":"crossref","unstructured":"Schroeder M, Abushamma S, George AT, Balakrishna R, Hickman J, Elumalai A, Wise P, Zulfiqar M, Ludwig DR, Shetty A, Viswanath SE (2024) Geldof expert consensus classification of perianal fistulizing Crohn\u2019s disease: a real-world application in a serial fistula MRI cohort. medRxiv 2024-02","DOI":"10.1101\/2024.02.03.24302160"},{"key":"3161_CR17","unstructured":"GONDOMAR Version 1.0, Dated 18.05.2021. In: Health Res. Auth. https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/application-summaries\/research-summaries\/gondomar-version-10-dated-18052021\/. Accessed 24 Nov 2024"},{"key":"3161_CR18","unstructured":"Eglinton DTW Perianal Crohn\u2019s Disease in Canterbury, New Zealand"},{"key":"3161_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy120","author":"WY Mak","year":"2018","unstructured":"Mak WY, Mak OS, Lee CK et al (2018) Significant medical and surgical morbidity in perianal Crohn\u2019s disease: results from a territory-wide study. J Crohns Colitis. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy120","journal-title":"J Crohns Colitis"},{"key":"3161_CR20","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0300-5089(21)00452-1","volume":"9","author":"P Buchmann","year":"1980","unstructured":"Buchmann P, Alexander-williams J (1980) 7\u2014Classification of perianal Crohn\u2019s disease. Clin Gastroenterol 9:323\u2013330. https:\/\/doi.org\/10.1016\/S0300-5089(21)00452-1","journal-title":"Clin Gastroenterol"},{"key":"3161_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/00000658-197502000-00015","volume":"181","author":"AJ Greenstein","year":"1975","unstructured":"Greenstein AJ, Sachar DB, Kark AE (1975) Stricture of the anorectum in Crohns disease involving the colon. Ann Surg 181:207","journal-title":"Ann Surg"},{"key":"3161_CR22","unstructured":"Journal of Pediatric Gastroenterology and Nutrition\u2014Wiley Online Library. https:\/\/onlinelibrary.wiley.com\/journal\/15364801. Accessed 24 Nov 2024"},{"key":"3161_CR23","doi-asserted-by":"publisher","first-page":"5371","DOI":"10.3748\/wjg.v23.i29.5371","volume":"23","author":"C Horaist","year":"2017","unstructured":"Horaist C, de Parades V, Abramowitz L et al (2017) Elaboration and validation of Crohn\u2019s disease anoperineal lesions consensual definitions. World J Gastroenterol 23:5371. https:\/\/doi.org\/10.3748\/wjg.v23.i29.5371","journal-title":"World J Gastroenterol"},{"key":"3161_CR24","unstructured":"Journal of Pediatric Gastroenterology and Nutrition. In: Wiley Online Libr. https:\/\/onlinelibrary.wiley.com\/journal\/15364801. Accessed 24 Nov 2024"},{"key":"3161_CR25","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S2468-1253(22)00088-7","volume":"7","author":"EM Meima-van Praag","year":"2022","unstructured":"Meima-van Praag EM, van Rijn KL, Wasmann KATGM et al (2022) Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy in the treatment of perianal fistulas in Crohn\u2019s disease (PISA-II): a patient preference randomised trial. Lancet Gastroenterol Hepatol 7:617\u2013626. https:\/\/doi.org\/10.1016\/S2468-1253(22)00088-7","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3161_CR26","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1093\/ibd\/izab361","volume":"28","author":"J Pan\u00e9s","year":"2022","unstructured":"Pan\u00e9s J, Bouma G, Ferrante M et al (2022) INSPECT: a retrospective study to evaluate long-term effectiveness and safety of darvadstrocel in patients with perianal fistulizing Crohn\u2019s disease treated in the ADMIRE-CD trial. Inflamm Bowel Dis 28:1737\u20131745. https:\/\/doi.org\/10.1093\/ibd\/izab361","journal-title":"Inflamm Bowel Dis"},{"key":"3161_CR27","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1093\/ecco-jcc\/jjaa004","volume":"14","author":"KA Wasmann","year":"2020","unstructured":"Wasmann KA, de Groof EJ, Stellingwerf ME et al (2020) Treatment of perianal fistulas in Crohn\u2019s disease, seton versus anti-TNF versus surgical closure following anti-TNF [PISA]: a randomised controlled trial. J Crohns Colitis 14:1049\u20131056. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa004","journal-title":"J Crohns Colitis"},{"key":"3161_CR28","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","volume":"132","author":"J-F Colombel","year":"2007","unstructured":"Colombel J-F, Sandborn WJ, Rutgeerts P et al (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial. Gastroenterology 132:52\u201365. https:\/\/doi.org\/10.1053\/j.gastro.2006.11.041","journal-title":"Gastroenterology"},{"key":"3161_CR29","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1093\/ecco-jcc\/jjae003","volume":"18","author":"W Reinisch","year":"2024","unstructured":"Reinisch W, Colombel J-F, D\u2019Haens GR et al (2024) Efficacy and safety of filgotinib for the treatment of perianal fistulising Crohn\u2019s disease [DIVERGENCE 2]: a phase 2, randomised, placebo-controlled trial. J Crohns Colitis 18:864\u2013874. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae003","journal-title":"J Crohns Colitis"},{"key":"3161_CR30","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1097\/MIB.0000000000000409","volume":"21","author":"DM Wiese","year":"2015","unstructured":"Wiese DM, Beaulieu D, Slaughter JC et al (2015) Use of endoscopic ultrasound to guide adalimumab treatment in perianal Crohn\u2019s disease results in faster fistula healing. Inflamm Bowel Dis 21:1594\u20131599. https:\/\/doi.org\/10.1097\/MIB.0000000000000409","journal-title":"Inflamm Bowel Dis"},{"key":"3161_CR31","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1111\/j.1365-2036.2006.02878.x","volume":"23","author":"BE Sands","year":"2006","unstructured":"Sands BE, Blank MA, Diamond RH et al (2006) Maintenance infliximab does not result in increased abscess development in fistulizing Crohn\u2019s disease: results from the ACCENT II study. Aliment Pharmacol Ther 23:1127\u20131136. https:\/\/doi.org\/10.1111\/j.1365-2036.2006.02878.x","journal-title":"Aliment Pharmacol Ther"},{"key":"3161_CR32","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/j.1365-2036.2010.04466.x","volume":"32","author":"S Lichtiger","year":"2010","unstructured":"Lichtiger S, Binion DG, Wolf DC et al (2010) The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn\u2019s disease who failed prior infliximab therapy. Aliment Pharmacol Ther 32:1228\u20131239. https:\/\/doi.org\/10.1111\/j.1365-2036.2010.04466.x","journal-title":"Aliment Pharmacol Ther"},{"key":"3161_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-304488","author":"P Dewint","year":"2013","unstructured":"Dewint P, Hansen B, Verhey E et al (2013) Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn\u2019s disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut. https:\/\/doi.org\/10.1136\/gutjnl-2013-304488","journal-title":"Gut"},{"key":"3161_CR34","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1053\/j.gastro.2015.06.014","volume":"149","author":"I Molendijk","year":"2015","unstructured":"Molendijk I, Bonsing BA, Roelofs H et al (2015) Allogeneic bone marrow-derived mesenchymal stromal cells promote healing of refractory perianal fistulas in patients with Crohn\u2019s disease. Gastroenterology 149:918-927.e6. https:\/\/doi.org\/10.1053\/j.gastro.2015.06.014","journal-title":"Gastroenterology"},{"key":"3161_CR35","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1053\/j.gastro.2010.02.013","volume":"138","author":"J-C Grimaud","year":"2010","unstructured":"Grimaud J-C, Munoz-Bongrand N, Siproudhis L et al (2010) Fibrin glue is effective healing perianal fistulas in patients with Crohn\u2019s disease. Gastroenterology 138:2275-2281.e1. https:\/\/doi.org\/10.1053\/j.gastro.2010.02.013","journal-title":"Gastroenterology"},{"key":"3161_CR36","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1002\/bjs.7121","volume":"97","author":"Y Maeda","year":"2010","unstructured":"Maeda Y, Ng SC, Durdey P et al (2010) Randomized clinical trial of metronidazole ointment versus placebo in perianal Crohn\u2019s disease. Br J Surg 97:1340\u20131347. https:\/\/doi.org\/10.1002\/bjs.7121","journal-title":"Br J Surg"},{"key":"3161_CR37","doi-asserted-by":"publisher","first-page":"102045","DOI":"10.1016\/j.eclinm.2023.102045","volume":"61","author":"EM Meima-Van Praag","year":"2023","unstructured":"Meima-Van Praag EM, Becker MAJ, Van Rijn KL et al (2023) Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy alone for Crohn\u2019s perianal fistulas (PISA-II): long-term outcomes of an international, multicentre patient preference, randomised controlled trial. eClinicalMedicine 61:102045. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102045","journal-title":"eClinicalMedicine"},{"key":"3161_CR38","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/DCR.0000000000002579","volume":"66","author":"EJ Dozois","year":"2023","unstructured":"Dozois EJ, Lightner AL, Dietz AB et al (2023) Durable response in patients with refractory fistulizing perianal Crohn\u2019s disease using autologous mesenchymal stem cells on a dissolvable matrix: results from the phase I stem cell on matrix plug trial. Dis Colon Rectum 66:243\u2013252. https:\/\/doi.org\/10.1097\/DCR.0000000000002579","journal-title":"Dis Colon Rectum"},{"key":"3161_CR39","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.cgh.2021.09.028","volume":"20","author":"DA Schwartz","year":"2022","unstructured":"Schwartz DA, Peyrin-Biroulet L, Lasch K et al (2022) Efficacy and safety of 2 vedolizumab intravenous regimens for perianal fistulizing Crohn\u2019s disease: ENTERPRISE study. Clin Gastroenterol Hepatol 20:1059-1067.e9. https:\/\/doi.org\/10.1016\/j.cgh.2021.09.028","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Techniques in Coloproctology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10151-025-03161-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10151-025-03161-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10151-025-03161-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T09:58:57Z","timestamp":1766051937000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10151-025-03161-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3161"],"URL":"https:\/\/doi.org\/10.1007\/s10151-025-03161-z","relation":{},"ISSN":["1123-6337","1128-045X"],"issn-type":[{"value":"1123-6337","type":"print"},{"value":"1128-045X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"9 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No patients were involved in the development of this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not commissioned, externally peer reviewed.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Provenance and peer review"}}],"article-number":"123"}}